Loading data for CMMB — first visit, this takes a few seconds.

Alerta

Chemomab Therapeutics Ltd... (CMMB)

NasdaqCM: CMMB · Precio en tiempo real · USD

1.91

-0.01 (-0.52%)

Al cierre: Aug 19, 2026, 8:00 PM

2.11

+1.12%

Fuera de horario: 5:57 PM

-0.52% (1D)

No hay datos disponibles

Precio de compra	1.4
Capitalización de mercado	15.31M
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-7.45M
Beta	0.66
EPS (TTM)	-1.12
Ratio PER (TTM)	n/a
Adelante PE	-69.67
P/B (TTM)	1.41
P/S (TTM)	n/a
Earnings Date	Nov 20, 2025

Precio de venta	1.82
Volumen	17,252
Volumen medio (20D)	131,353
Abierto	1.92
Anterior Cerrar	1.92
Rango del día	1.87 - 1.92
Rango de 52 semanas	1.35 - 4.12
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de CMMB

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as ...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Feb 12, 2019

Empleados n/a

Bolsa de Valores NasdaqCM

Símbolo bursátil CMMB

Sitio web https://www.chemomab.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Chemomab Therapeutics fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -8.99M, una disminución de -35.5%.

Estados financieros

Sorpresa de resultados

Chemomab Therapeutics ha publicado sus resultados trimestrales en Aug 14, 2025:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.

EPS de -0.02 supera las estimaciones en 0.02, con -140.00% Disminución interanual.

Próxima publicación de resultados

Está previsto que Chemomab Therapeutics Ltd. publique sus resultados el Nov 20, 2025, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

10 meses hace · Zacks

ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition

Alkermes inks $2.1B deal to acquire Avadel, adding the latter's Lumryz and new growth potential to its portfolio.

10 meses hace · Zacks

SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study

Sanofi's efdoralprin alfa meets all key endpoints in a global phase II study, showing potential as a first restorative recombinant therapy for AATD.

10 meses hace · Zacks

ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up

Esperion selects ESP-2001 as a preclinical candidate for primary sclerosing cholangitis, a rare liver disease, aiming to begin clinical studies in 2026.

10 meses hace · Zacks

Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan

VTRS acquires Aculys Pharma to boost its CNS portfolio in Japan, gaining rights to pitolisant and Spydia for narcolepsy and seizure management, respectively.

10 meses hace · Zacks

RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy

Rocket Pharmaceuticals surges as the FDA accepts its resubmitted BLA for Kresladi, a gene therapy targeting the rare LAD-I disorder.

Página 1 de 2

Chemomab Therapeutics Ltd... (CMMB)